Alterity Therapeutics (ATHE) FCF Margin (2016 - 2019)

Alterity Therapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 138.97% for Q4 2019.

• In Q4 2019, FCF Margin rose 43995.0% year-over-year to 138.97%; the TTM figure through Dec 2019 stood at 314.25% (up 1778.0% YoY), while the FY2024 annual figure was 12.08%, changed N/A from the prior year.
• FCF Margin for Q4 2019 stood at 138.97%, up from 300.98% in the prior quarter.
• The five-year high for FCF Margin was 1027.32% in Q4 2017, with the low at 300.98% in Q4 2018.
• The 4-year median for FCF Margin is 52.37% (2019), against an average of 207.77%.
• The sharpest annual moves came in 2017 and 2018: FCF Margin soared 106154 bps in 2017, then sank 132830 bps in 2018.
• Alterity Therapeutics' FCF Margin stood at 34.22% in 2016, then jumped by 3102 bps to 1027.32% in 2017, then slumped by 129 bps to 300.98% in 2018, then jumped by 146 bps to 138.97% in 2019.
• Business Quant data shows ATHE's FCF Margin at 138.97% in Q4 2019, 300.98% in Q4 2018, and 1027.32% in Q4 2017.